Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Airway and Aystemic Inflammation in Cystic Fibrosis: A Systematic Review
{{output}}
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has transformed clinical outcomes in people with cystic fibrosis (PwCF), but its impact on airway and systemic inflammation is less well defined. ... ...
